



*Working with a mixed partnership:
new approaches to E-based
learning delivery*

Ms. Jurate Svarcaite

Research Co-ordinator,
School of Pharmacy, University of London.

Project: Self-medication related competencies for
European pharmacy students and pharmacists.



Drivers for Change...

1. Professional knowledge and patient safety

2. Changing health care systems

Chronic care delivered in the community

Public health via Pharmacies

Clinical – managing therapy; patient services

3. Workforce issues:

Expectations & changing roles of pharmacists – “responsibility & accountability”

Competence – “fitness to practice”

Performance – do professionals deliver what is needed?



Why is competence so important?


'A patient is entitled to be cared for and by healthcare professionals with relevant and up-to-date skills and expertise.'

Kennedy Report (p14)



Competency iceberg

Effective and
persistent behaviour



Knowledge

Skills

Abilities

Values, attitudes



Moving on...

Practitioner continuing development & education
...and the self care medicines agenda

AESGP Pilot Project

New ways of delivering and accessing CPD resources

European Pharmaceutical Students' Association (EPSA)

Association of the European Self-Medication Industry (AESGP)

School of Pharmacy University of London



Self-care related competencies for European pharmacists and pharmacy students:

The project

- Aims to develop a useful (and holistic) CPD framework and self-assessment tools for community pharmacy practitioners.
- Aims to develop and make available online resources to support practitioner development (within the workplace) and enhance medicines expertise.
- To provide a common platform for practitioners to maintain competence within the medicines agenda.



The Concept





Resource Development

Basic components:

- Learning resources (open source information; practitioner driven; Communities of Practice)
- Patient Case scenarios
- Pool of self-assessment questions
- Information trees for each core area (site trees)
- Developmental Framework “competency framework” for practitioner development



Why expend this effort?

1. Evidence and best practice needs to be implemented
2. Existing tools/resources inadequate
3. Leadership and collaboration between partners as an exemplar



Why expend this effort?

1. Evidence and best practice needs to be implemented
2. **Existing tools/resources inadequate**
3. Leadership and collaboration between partners as an exemplar



Google it!

Try searching using key words statin and
cardiovascular risk

361 000 results


None of the first few pages are useful for practice!



Simvastatin

From Wikipedia, the free encyclopedia

Simvastatin (INN) (pronounced /'simvəstætin/), (marketed under the trade names **Zocor**, Simvastatin, Simlup, Simcard and others) is a **hypolipidemic drug** belonging to the class of pharmaceuticals called "**statins**". It is used to control **hypercholesterolemia** (elevated **cholesterol** levels) and to prevent...



Metabolic activation,
 hence liver (dys)function important,
 hence clinical monitoring important,
 hence other drug therapy important,
 hence dosage and use important,
 hence patient counselling important,
 hence....

- navigation
- [Main page](#)
 - [Contents](#)
 - [Featured content](#)
 - [Current events](#)
 - [Random article](#)
- search
- Pharmacy
-
- interaction
- [About Wikipedia](#)
 - [Community portal](#)
 - [Recent changes](#)
 - [Contact Wikipedia](#)
 - [Donate to Wikipedia](#)

- Contents** [hide]
- 1 History
 - 2 Uses
 - 3 Cost / benefit
 - 4 Pharmacology and interactions
 - 4.1 Interactions
 - 5 Side effects
 - 6 Marketing



Why expend this effort?

1. Evidence and best practice needs to be implemented
2. Existing tools/resources inadequate
3. **Leadership and collaboration between partners as an exemplar**

- Main Page
- Cardiology Syllabus
- CVD Risk Management
- Cardiovascular System
- CV Disease
- CVD Prevention
- Recent changes
- Help

Search

Search input field with Go and Search buttons

Toolbox

- What links here
- Related changes
- Upload file
- Special pages
- Printable version
- Permanent link




Welcome to the **Pharmahost.org!**

Pharmahost.org is a collaborative knowledge and expertise about medicines sharing platform. Currently covering cardiovascular disease and risk management with special focus on OTC medicines and self-care topics.

It is created by pharmacy practitioners to be used by pharmacy students and other practitioners. The site is created using MediaWiki software. It is a long term project, all contributions are welcome.

Read more about [Pharmahost.org Project](#)



Index

[\[edit\]](#)

Index


- European General Level Pharmacy Practice
 - Personal Competencies
 - [\[Personal Organisation\]](#)
 - [\[Personal Communication\]](#)
 - [\[Personal Teamwork\]](#)
 - [\[Personal Professionalism\]](#)
 - Problem Solving Competencies
 - [\[Problem Solving\]](#)

Go Search

- Toolbox**
- What links here
 - Related changes
 - Upload file
 - Special pages
 - Printable version
 - Permanent link

Index [\[edit\]](#)


- Index
 - European General Level Pharmacy Practice
 - Personal Competencies
 - [\[Personal Organisation\]](#)
 - [\[Personal Communication\]](#)
 - [\[Personal Teamwork\]](#)
 - [\[Personal Professionalism\]](#)
 - Problem Solving Competencies
 - [\[Problem Solving\]](#)
 - Articles
 - [All the articles](#)
 - [Missing articles](#)
 - Communities of Practice
 - [Cardiology](#)
 - Assessment
 - [All Questions](#)
 - [All Patient Cases](#)



Administrative Sport [\[edit\]](#)

[Go to previous Main Page](#)

[Go to Wiki Tutorial](#)



Submitting Questions - Windows Internet Explorer
http://elearn.pharmacy.ac.uk/aesgp/questions.asp
File Edit View Favorites Tools Help
Google Search mywebsearch MyFunCards Smiley Central Screensavers Cursor Mania
Submitting Questions

AESPG - GLF


Results

'VB Script Document

Date submitted: 02/06/2009 12:36:13

Your score for Professionalism: **18 / 44**
This is a **poor** score so we suggest that you now go to [this information page](#)

Go back to [main page](#)



Redirects user to information

Help

Search

Go Search

Toolbox

- Absorption and bioavailability
- Acute Coronary Syndromes Curriculum
- Age and gender
- All Patient Cases
- Alpha-glucosidase inhibitors
- Angiotensin II receptor blockers
- Anticoagulants
- Antiplatelet effects of aspirin
- Arrhythmias
- Aspirin Case Scenarion
- Aspirin assessment Questions I
- Asprin and GI
- Atrial Fibrillation Curriculum
- Biguanides
- Bradycardia
- Calcium-channel blockers
- Cardiology Syllabus
- Cardiovascular system
- Centrally acting antihypertensive drugs
- Clopidrogel
- Connestive Heart Failure
- Acetylsalicylic Acid
- Administrative support
- Air intake and oxygenation of blood
- All Questions
- Angina pectoris
- Anti-arrhythmic drugs
- Antiplatelet Trialists Collaboration meta-analysis
- Antiproliferative effects
- Arteries, capillaries, and veins
- Aspirin History
- Aspirin question set
- Assessment Questions I
- Behaviour change
- Biosynthesis of anti-inflammatory mediators
- Brussels Demonstration
- Cardiac cycle
- Cardioprotective diet
- Causes and risks of hypertension
- Cerebrovascular circulation
- Common.css
- Coronary arteries
- Acute Coronary Syndromes
- Adrenergic neurone blocking drugs
- Alcohol consumption
- Alpha-adrenoreceptor blocking drugs
- Angiotensin-converting-enzyme inhibitors
- Anti-inflammatory effects
- Antiplatelet drugs
- Appropriate risk calculator
- Aspirin Assessment
- Aspirin and Inflammation
- Aspirin Map
- Atherosclerosis
- Beta-blockers
- Blood pressure
- CVRM
- Cardiology
- Cardiovascular disease (CVD)
- Causes of endothelial dysfunction
- Classification of blood pressure
- Conduction system
- Coronary artery disease

Acetylsalicylic Acid

JURATE MY TALK MY PREFERENCES MY WATCHLIST MY CONTRIBUTIONS LOG OUT

Navigation page [discussion](#) [edit](#) [history](#) [delete](#) [move](#) [protect](#) [watch](#)

- Main Page
- Cardiology Syllabus
- CVD Risk Management
- Cardiovascular System
- CV Disease
- CVD Prevention
- Recent changes
- Help

Search

Go Search

- Toolbox
- What links here
 - Related changes
 - Upload file
 - Special pages
 - Printable version
 - Permanent link

Contents [hide]

- 1 Introduction
- 2 Mechanism of action
- 3 Pharmacology and pharmacokinetics
- 4 Indications
- 5 Cautions
- 6 Contra-indications
- 7 Side-effects
- 8 Dose
- 9 Other Useful Information
- 10 External Links
- 11 Self-Assessment



Introduction [\[edit\]](#)

Acetylsalicylic acid has been hailed as a "wonder drug of the 20th and 21st centuries." Since the early use of acetylsalicylic acid for the relief of pain and inflammation, more has been learned about the other beneficial properties of acetylsalicylic acid, particularly the ability to inhibit platelet aggregation and thus to reduce the risk of cardiovascular (CV) events. As investigative techniques have been refined to the molecular level, still more has been, and is being, learned about its protective effects on other aspects of cardiovascular disease (CVD), such as improvement of endothelial function.

treatment of acetylsalicylic 75 mg/day for further CVD prevention.

- **Long-term** use of low-dose acetylsalicylic acid (75 mg/day) is beneficial to patients with established cardiovascular disease, for patients with a 10-year cardiovascular disease risk of 20% and more and aged over 50 years, for patients with diabetes aged over 50 years or who have diabetes for more than 10 years, and for patients with diabetes who are receiving antihypertensive treatment.

!NB! Blood pressure must be controlled before acetylsalicylic acid is given.

- Low-dose acetylsalicylic acid (75 mg/day) is also given following coronary bypass surgery.

!NB! If the patient is at high risk of gastro-intestinal bleeding, a proton-pump inhibitor can be added.

Other Useful Information

[\[edit\]](#)

- Key clinical trials of acetylsalicylic acid use in CVD management
- New targets for acetylsalicylic acid in CVD: emerging science

External Links

[\[edit\]](#)

Self-Assessment

[\[edit\]](#)

[Patient Case Assess](#)

[Aspirin assessment Questions I](#)

- Cardiology Syllabus
- CVD Risk Management
- Cardiovascular System
- CV Disease
- CVD Prevention
- Recent changes
- Help

Search

Go Search

Toolbox

- What links here
- Related changes
- Upload file
- Special pages
- Printable version
- Permanent link

3. Before starting antiplatelet treatment for primary prevention of cardiovascular disease, which of the following is true?



- A. Cholesterol level should be controlled under 5mmol/l
- B. Blood pressure should be controlled under 150/90 mmHg
- C. Coagulation of blood should be checked
- D. GI tract screening performed

Continue





“Communities of Practice”

Collaboration portal

List of Editors

Credentialing for practitioners (portfolio and regulation)

Cardiology

JURATE MY TALK MY PREFERENCES MY WATCHLIST MY CONTRIBUTIONS LOG OUT

Navigation page [discussion](#) [edit](#) [history](#) [delete](#) [move](#) [protect](#) [watch](#)

- Main Page
- Cardiology Syllabus
- CVD Risk Management
- Cardiovascular System
- CV Disease
- CVD Prevention
- Recent changes
- Help

Search

Go Search

Toolbox

- What links here
- Related changes
- Upload file
- Special pages
- Printable version
- Permanent link



Contents [hide]

- 1 Introduction
- 2 Members
- 3 Editors
- 4 Practice

Introduction [\[edit\]](#)

Members [\[edit\]](#)

Jurate Svarcaite

Editors [\[edit\]](#)

- Jurate Svarcaite

Practice [\[edit\]](#)

- Cardiovascular risk and disease management



Navigation

user page [discussion](#) [edit](#) [history](#) [delete](#) [move](#) [protect](#) [watch](#)

- Main Page
- Cardiology Syllabus
- CVD Risk Management
- Cardiovascular System
- CV Disease
- CVD Prevention
- Recent changes
- Help

Search

Toolbox

- What links here
- Related changes
- User contributions
- Logs
- Block user
- E-mail this user
- Upload file

Contents [hide]

- 1 Current Position
- 2 Professional Summary
- 3 Education
- 4 Experience
- 5 Honors and Awards
- 6 Membership
- 7 Publications
- 8 Disclosures
- 9 CV
- 10 Contacts
- 11 Community of Practice



Current Position

[\[edit\]](#)

Research Co-ordinator, the London School of Pharmacy, UK

Professional Summary

[\[edit\]](#)

Hold a Masters degree in Pharmacy. Currently studying MSc in Pharmacy Practice in the London School of Pharmacy, University of London.



New IT educational technology coupled with a new
vision

General Level Framework

Structured Professional Development



Operational CPD

Fitness to practice



Patient Safety and access

'Informed Patient'

Better Outcomes



JOINT
PROGRAMMES
BOARD



Competency Development & Evaluation Group

Models for Practitioner Development

Professor Ian Bates
Professor Graham Davies
Mr David Webb, Visiting Professor
Mr Duncan McRobbie, Visiting Professor
Ms Alison Innes, Advanced Practice
Dr Catherine Duggan, Advanced Practice

Downloads:

www.codeg.org

www.postgraduatepharmacy.org



University of Brighton

